Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

Br J Haematol. 1998 Sep;102(5):1115-23. doi: 10.1046/j.1365-2141.1998.00930.x.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Disease Progression
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Multiple Myeloma / therapy*
  • Recurrence
  • Treatment Outcome


  • Antineoplastic Agents